Comprehensive PASS-powered elucidation of phytoconstituent therapeutic profiles for advanced psoriasis intervention strategies

Abstract

Psoriasis is a chronic inflammatory skin disease marked by immune dysregulation, leading to rapid skin cell turnover and formation of thick, red, scaly plaques, mainly on the scalp, elbows, knees, and lower back. These plaques cause itching, pain, and significant quality-of-life impairment. The most common form, plaque psoriasis, accounts for 80–90% of cases. Although the Th17/IL-23 pathway is known to play a key role in disease pathogenesis, variability in disease progression and response to biologic therapies underlines the need for more personalized treatments. Recently, natural products have gained interest for their anti-inflammatory and immunomodulatory effects in psoriasis management. Compounds like curcumin, quercetin, and naringin have shown beneficial modulation of key inflammatory pathways. Pharmacological studies using computational tools (PASS software) have predicted bioactivities of plant-derived compounds such as quercetin, curcumin, kaempferol, stigmasterol, taraxerol, aloesin, emodin, and mukulol against biological targets linked to psoriasis—including tumor necrosis factor-α, antioxidant enzymes, lipoxygenase, cytochrome P450, and Janus kinase. This integrated investigation supports the therapeutic promise of these natural compounds for psoriasis, suggesting potential for developing more effective and targeted treatments.